AICAR

AICAR (5-Aminoimidazole-4-carboxamide ribonucleoside, Acadesine) is an adenosine analog that activates AMP-activated protein kinase (AMPK), a master regulator of cellular energy homeostasis. AMPK activation mimics many metabolic effects of exercise, leading to AICAR's classification as an "exercise mimetic." Research demonstrates AICAR enhances fat oxidation, improves glucose uptake in skeletal muscle, increases mitochondrial biogenesis, and enhances endurance capacity. Studies in mice showed 44% improvement in running endurance without exercise training. The compound activates AMPK by being converted to ZMP, which mimics the effects of elevated AMP levels. Beyond metabolic effects, AMPK activation influences autophagy, inflammation, and cellular stress responses. Research indicates potential applications for obesity, type 2 diabetes, metabolic syndrome, and conditions of physical deconditioning. AICAR was initially developed for cardiac ischemia protection and has cardioprotective properties. The compound is prohibited by WADA in competitive sports due to its performance-enhancing effects.

Human data come from failed cardiac-surgery trials and pharmacokinetic studies, not performance research. No human trial supports endurance, fat-loss, or muscle claims, and the oral bioavailability and dosing used by consumers are uncharacterized in humans.

A purine nucleoside analog that is phosphorylated to ZMP, an AMP mimetic that activates AMPK. Clinical studies administered it intravenously with a short plasma half-life; oral use is not supported by human pharmacokinetic data.